This paper, which is published in two parts, reviews the literature pertaining to antiviral chemotherapy of viruses of veterinary importance. While early reports in the 1970s referred to the chemotherapy of a number of different RNA and DNA viruses, there' was considerable focus in the 1980s, initially on herpesviruses and latterly on retroviruses, and particularly in cats. Details are given of the successful treatments of FeLV and FIV, which have been used as animal models for HIV therapy. 'Therapy of equine, canine, bovine, porcine, avian, and fish diseases is also considered. The high costs of developing and registering a new chemical entity, especially for food species in which extensive toxicity/residue data are required, is the main reason why specific antiviral compounds are not currently available for veterinary use, although some non-specific immune modulators are now emerging. Concurrent availability of appropriate diagnostic tools is a prerequisite for successful veterinary antiviral chemotherapy, as is a greater understanding of the pathogenesis of virus infections in animals and the development of more sophisticated means of drug delivery, appropriate to both food animal species and companion animals (dogs, cats, and horses). Additionally, antiviral agents are valuable as research tools per se, as opposed to solely as chemotherapeutic agents. Part 1 covers the feline virus diseases, while part 2 includes the other viruses~f veterinary importance, in dogs, horses, cattle, pigs, birds, and fish.
Introduction
Antiviral chemotherapy in the veterinary field remains at Received 26 March, 1992; revised and accepted 8 May, 1992 the early stages of development, although it is almost 30 years since the concept of antiviral chemotherapy became an actuality. While a number are available for the treatment of virus infections in humans, to date, no specific antiviral compounds have been licensed solely for veterinary use. Indeed, compounds such as acyclovir (Zovirax®) and zidovudine (Retrovir®) have been so successful, that they now represent some 43% of total sales of The Wellcome Foundation pic, with turnovers for the half-year to February 1992 of £278 million for Zovirax'" and £103 million for Retrovir®,up over 30% on 1991 (Anon, 1992b) . In humans, . antivirals are almost exclusively restricted to treatment of herpes or retrovirus infections. The two main reasons for the absence of antiviral drugs for veterinary use is the high cost of development coupled with narrow spectrum of activity. There has been a lack of investment in targeted antiviral research programmes in animal health, because of the likely poor return on such investment. The development of a new chemical entity, particularly for use in food species, costs in the region of £10 million and takes approximately 10 years, because of the extensive safety/toxicity/residue testing required for product registration. While this investment may be justified for a broad spectrum antibacterial which can be used in several different species against a number of diseases, it is unlikely to be so for an antiviral compound, which could be useful against a single virus in a restricted number of species.
The concept of a really 'broad spectrum antiviral' (other than non-specific immunomodulators or cytokines) will be difficult to realize since, to date, a broader spectrum of action has normally been associated with host cell toxicity. For example, while acyclovir (ACV) had good activity against equine herpes virus 1 (EHV-1), only poor activity was reported against the other herpes viruses of domestic animals, SHV-1 (porcine), BHV-1 [bovine), FHV-1 (feline) (Rollinson and White, 1983) , and acyclovir shows no activity against other DNA viruses or against RNA viruses such as TGE, transmissible gastoenteritis, a member of the Coronaviridae (Rollinson, 1988) . However, the advent of compounds such as HPMPA and HPMPC, which do have a relatively broad spectrum of activity but low toxicity, is encouraging.
The specificity of action of acyclovir, and similar nucleoside analogues, is due to the fact that such compounds require conversion to the active triphosphate form within virus-infected cells. The phosphorylation to the monoand/or diphosphate is catalysed by the virus-specified thymidine kinase (TK). The ACV triphosphate then acts as a substrate for viral DNA polymerase and inhibits further DNA synthesis by chain termination. The relatively low sensitivity of BHV-1 to acyclovir results from the nucleoside analogue not being a good substrate for the viral TK (Weinmaster et al., 1982) .
Evenif specific veterinary antivirals were available, there remains a practical problem in the timing of treatment. Generally, by the time clinical signs of virus infection are apparent, in acute infection at least, and the disease has been diagnosed, much of the viral replication and consequent pathological changes will have already taken place. In these cases, antiviral chemotherapy is likely to be of limited value, except in in-contact animals not yet showing signs, and symptomatic therapy is likely to be the only practical approach. However, this limitation used to be attributed to human antivirals, and has since been proved untenable. The importance of rapid, specific diagnostic tools as a fundamental basis of antiviral therapy cannot be stressed too strongly. Although, there is currently much effort in this field, the emphasis is on development of diagnostics to accompany viral vaccines, either to ascertain whether vaccination is necessary or has been successful, rather than for the diagnosis of infections.
Notwithstanding the above reservations, the research effort on the human front has greatly intensified since the advent of HIV (human immunodeficiency virus) and AIDS (acquired immunodeficiency syndrome) and the search for anti-retroviral drugs is likely to lead to the discovery of potential compounds for veterinary use. Furthermore, animals models e.g. FeLV and FIV are being used in the screening process for human antivirals. In two parts, this paper provides an update on earlier reviews (Gustafson, 1980; White, 1981; Rollinson, 1988) and will demonstrate how the initiatives in human antiviral research will impact on the prospects for the veterinary field. There are innumerable reports of activity in vitro of many antivirals against viruses which are only of veterinary importance (see Rollinson, 1988) as well as reports where antiviral agents have been used solely as research tools per se. While referring to in vitro activity where appropriate. this review will be largely restricted to reports of in vivo testing.
Summary tables are given, by species, listing the virus diseases against which antiviral agents have been tested in vivo in the target host, together with the compounds tested and their actlvlties, as follows: In part 1, Table 1A on feline diseases, followed in part 2 by: Table 1B, avian  diseases; Table 1C, bovine diseases; Table 1D, porcine  diseases; Table 1E, equine diseases; Table ,1 F, canine   diseases; and Table 1G , fish diseases. Details of these reports are given in the text, with the emphasis on retroviruses and herpesviruses, reflecting the relatively large effort in these areas. Apart from a brief mention by White (1981) of a lack of activity of the antipox drug methisazone against orf infection, there are no reports of testing antivirals against ovine viruses in sheep, although visna virus has been used as an in vitro model for HIV (Frank et al., 1987) . However, there are two reports of sheep being used as a model in vivo system for testing suramin against bovine leukaemia virus, to which sheep are susceptible (Burkhardt and Ros, 1989; Rosenthal et al., 1990) . Prior to doing studies in the target host, dose-ranging work is frequently done in laboratory animal models. The currently available models for viruses of veterinary importance are listed in Table 2 , part 2 together with the compounds tested and their relative activities. It is of interest to note that there is not always good correlation between these models and activity in the target species. A review of several animal models used to assess human antivirals is given by Field and Brown (1989) .
Avian herpesviruses
A review on the significance of antiviral chemotherapy to the poultry industry is given by Gustafson (1980 (Schwers et al., 1980 (Schwers et al., , 1981 , but moderate activity against MDVand THV (Reno et aI., 1978) , (2) Ribavirin. Moderate activity against MDV (C. S. Edison, p~rsonal communication; Eidson et el., 1974) , (3) Acyclovir. Slight activity against PHV (Thiry et al., 1983) , with moderate activity against MDV and THV (Collins, 1983) , and (4) Fluoropyrimidine nucleosides (FIAC, FMAU, FIAU). High activity against MDV and THV (Schat et el., 1984) .
In vivo studies in the target species (see Table 1A ) have been disappointing with phosphonoacetic acid (PAA) and MDV (Lee et al., 1976) and Phosphonoformic acid (PFA) and PHV (Vindevogel et aI., 1982) . No positive effect was demonstrated in Marek's disease-infected chicks treated for 28 days at 500mg PAA kg-1 day" i.p, or in pigeon herpesvirus-infected pigeons and budgerigars treated for 10 days at 1OOmg PFA kg-1 day" i.rn, PHV infection also proved refractory to acyclovir treatment [100mg kg-1 day-1, i.rn., thrice daily] (Thiry et al., 1983) and MDV infection was not ameliorated by the interferon inducer, Poly I:C (Nemes et aI., 1969) . Cyclophospharnlde gave some protection «30%) against MDV in chickens (Lu et al. 1976; Yue-Shoung et et., 1976) . Eidson et at. (1974) sulphone Chang (1973 Chang ( ,1974 Field (1992a, 1992b) Bovine rotavirus Hu-IFN-a2 ++ van den Bielefeldt Ohmann et at. 5-hydroxyuracil (1985a, 1985b) Moderate activity in vivo against MOV was obtained with amino-ureidophenylsulphone (Chang, 1973 (Chang, , 1974 Eidson et al., 1974) , with dichlorodiphenyldichloroethane (Colmano and Gross, 1971) , with Statolon and with exogenous IFN (V. E. Vengris and C. J. Mare, personal communication). A study of the effects of in-feed amino acids lysine and argenine, which, respectively, have been reported to suppress the clinical manifestations of herpesvirus infections and enhance multiplication of herpesviruses, was undertaken in chickens infected with MOV, but no details have been published. Ribavirin was effective in reducing lesions in MOV experimentally infected chickens when administered s.c, (500mg kg-1 day:", twice daily injections for 2 weeks), but was ineffective when provided in feed (1 g 1001b-1 feed) to 1-day-old chickens for 6 weeks (C. S. Eidson, personal communication; Eidson etal., 1974) . Repeated parenteral treatment of communally reared chickens would not be economically feasible and it is unlikely that ribavirin would become a commercial reality for control of Marek's disease. Various other agents have been tested for their antiviral activity in poultry. Treatment with the two adrenal steroid-blocking agents, metyrapone and dlchlorodiphenyldichloroethane in feed (350 and 500mg kg-1, respectively), significantly reduced the severity of disease in herpes encephalitis virus-infected turkeys and Marek's disease virus-infected chickens, respectively (Colmano and Gross, 1971 ).There are no reports of chemotherapeutics providing over 80% protection in avian species with herpesvirus infections.
Other avian viruses
A report on the promising prophylactic activity of amantadine appeared in,970 against malignant influenza A in turkeys (Lang et aI., 1970) . Optimum effectiveness was obtained only with sustained administration of the drug over a 2-3 week period; infection was prevented, or remained subclinical, in about 80% of turkeys given a single oral dose (10mg kg-1) or when amantadine was incorporated into the feed pellets at 0.025 or 0:05% (:::;5mg kg-1 day-1). The minimum effective dose was of the order of 5 mg kg-1, giving 10-20% failures.
Studies on the efficacy of amantadine_against influenza A virus infection in quail were reported by Easterday (1975) , but it was not until 10 years later that another publication on its use in poultry appeared. Webster and co-workers (1985) showed that amantadine and rimantadine administered in drinking water (0.1 or 0.01%) were efficacious both prophylactically and therapeutically against an influenza A virus infection in chickens, which caused up to 80% mortality. However, under conditions simulating natural transmission of the virus, amantadineresistant mutant viruses arose within 9 days: all of the Antiviral chemistry in veterinary medicine 315 contacts were infected and approximately 50% died. Simultaneous administration of H5N2 vaccine and amantadine protected birds from infection, whereas vaccine alone did not. The efficacy of vaccine plus chemotherapeutic agent can be explained by the rapid response of chickens to vaccination with influenza virus. By the time amantadine-resistant viruses appeared (approximately 9 days after initial infection), the birds were immune. These results indicate that, should a highly virulent influenza outbreak appear, amantadine plus vaccine would be feasible, especially when eradication is not a viable option. In turkeys, amantadine was most effective when administered orally for at least two days after challenge (D. Karunakaran, personal communication). The protease inhibitors E-amino-H-caproic acid and aprotinin, when administered to influenza virus-infected chicks (every 3-6h i.rn. for 3 days), prevented the development of a generalized infection when therapy was commenced immediately (Zhirnov et el., 1983) . Moreover, when therapy was commenced 72 h post-infection, it blocked an already disseminated infection.
Newcastle DiseaseVirus (NOV) infection in chickens has provided another target for chemotherapy studies. Ribavirin proved effective in reducing mortality when administered orally (by gavage or in drinking water) to infected flocks of chickens in Pakistan (Anjum et al., 1982) . Treatment had no curative effect on severely affected birds, but did prolong their survival time. Ascorbic acid was inactive in vivo in NOV-infected chickens (Kramer et aI., 1973) . In pilot trials, the imidazolidone derivative Impacarzin, injected i.rn., prevented the development of clinical signs and mortality in NOV-infected chicks and adult chickens (E. F. Kaleta et al., personal communication). The therapeutic effect was dependent on the virus challenge and dose rate and also on the time interval between infection and treatment. In a study aimed at explaining why NOVvaccines sometimes fail to immunize recipient birds, it was found that butylated hydroxytoluene (BHl), a widely used antioxidant poultry feed additive, incorporated in diet at 100-200 ppm, prevented mortality of chickens exposed to virulent NOV and also prevented the serological response of chickens exposed to avirulent vaccine NOV (Brugh, 1977) . It was considered premature, on the basis of this study, to consider the clinical use of BHT for control of NOV, and important first to define the mechanism of apparent antiviral action of BHT. Whitfill et al. (1991) reported on what appears to be one of a newly identified class of non-specific antiviral agents produced in vivo in chickens in response to viral infection, with activity against NOV, infectious bursal disease virus, and infectious bronchitis virus. The virus neutralizing factor (VNF) acts as an in-contact inhibitor, rather than at the cellular level to prevent viral replication, ruling out that it is an IFN-agent. However, protective effects of VNF were not observed when given to chickens immediately, before, or 3 or 7 days prior to Rous sarcoma virus challenge.
The liver disease associated with Duck hepatitis B virus (DHBV) infection of domestic ducks provides a useful model for the human counterpart (Marion et aI., 1984) , but reports of antiviral activity against DHBV appear to be limited to in vitro studies (yokota et al., 1990) . Of a number of nucleoside analogues tested, (S)-HPMPA showed the highest activity, IC so 0.511-g mr',
Piscine viruses
The fish herpesviruses include Herpes virus salmonis (HVS), Oncorhynchus masou virus (OMV), and channel catfish virus (CCV). No activity against HVS and OMV was reported in in vitro studies with Ara-A (Kimura et el., 1983a) but CCV proved very susceptible (IC so <10 I1-M) (Buck and LOh, 1985) . The pyrophosphate analogues showed slight activity in vitro against CCV and moderate activity against OMV (Koment and Haines, 1978; Kimura et al., 1983a; Buck and LOh, 1985) . Idoxuridine and acyclovir on the other hand, were highly active in vitro, (IC so <10 I1-M) against CCV, OMV, and HVS and in vivo against OMV (Kimura et al., 1983b) . When IDU was provided in feed at a dose rate of 2511-g per fish per day for 60 days, or when fish were placed in water containing 2511-g IDU mr' mortality was delayed and reduced and tumour development markedly suppressed. The effect of ACV in reducing mortality and preventing tumour development in OMVinfected chum salmon fry was only evident when the fry were immersed in a 2511-g ACV rnr ' solution (30 min day" for 15-60 days), and was not seen in fish receiving ACV-medicated food (approximately 2511-g per fish per day), which is the preferred method of giving medication in practice.
A single 2-h exposure of infectious pancreatic necrosis virus (IPN)-infected fry to ribavirin doses as high as 400 I1-g mr' tank water resulted in only a slight decrease in the number of deaths (Savan and Dobos, 1980) . Whether repeated daily exposure of the fry would have produced better results was not investigated because, in a hatchery situation where the numbers of fish and size of tanks are so large, the cost of such a measure would be prohibitive.
In 1962, Economon showed that young brook trout that were fed polyvinylpyrrolidone-iodine (PVP-I) in their food ration showed a significant reduction in IPN morbidity and mortality. SUbsequent studies to determine the optimum dose regimen were not reported until 10 years later (Economon, 1973) . Brook trout fry were given PVP-I treated diet for 15 days to give an estimated intake of 1.64 available iodine kg day", A mortality of 17% was observed in the treated fish compared with 34% mortality in the untreated controls. The mode of action of PVP-I was not investigated, and no further studies with this compound have been reported. Hasobe and Saneyoshi (1985a) reported on the treatment ofthe rhabdovirus infectious hematopoietic necrosis virus (IHNV) in salmonid fishes by 6-TI (6-thioinosine) (O.111-g rnl") and 5-0HUrd (10 I1-g rnr') (1-[3-D-ribofuranosyl-5-hydroxyuracil), over a four-week period, either daily or on alternate days. The compounds were moderately effective, with life span increased in treated groups, with survival rates 26% and 20% higher, respectively. 5-0HUrd was less effective when given on alternate days.
Canine viruses
DHPG was inactive in vitro against canine herpesvirus (CHV) (Smith et aI., 1983; Ogilvie and Hanna, 1984) . Ribavirin showed high activity in vitro against canine parainfluenza virus (Povey, 1978) .
Isoprinosine was inactive in ferrets infected with canine distemper virus (Glasgow and Galasso, 1972) , while diethyl ether (inhaled) showed high activity (Donovan, 1968) .
Subcutaneous administration to dogs of poly I:C (0.2mg kg-1 ) 24h before i.v, inoculation of infectious canine hepatitis virus resulted only in longer survival of the treated compared with the untreated dogs (a mean survival time of 6.1 and 3.8 days, respectively) and no dogs survived (Wooley et aI., 1974) . The poor protection recorded may have been due to the fact that circulating IFN was not detectable in the dogs. The route of administration of the IFN inducer may greatly affect the IFN response. Thus, it cannot be argued that the IFN per se was ineffective, but rather the inducer was ineffective in promoting an adequate IFN response. The monoamine oxidase inhibitor nialamide (50mg kg-1 , in divided, thrice daily oral doses) was of therapeutic value in the treatment of experimental infectious canine hepatitis virus infection in dogs as determined by clinical signs, liver function tests, and histopathology (Cifuentes-Bernal et aI., 1968) .
Although there are reports on activity against rabies virus in vitro (e.g. Tsiang et aI., 1978 Tsiang et aI., , 1991 Hernandez-Jaurequi et al., 1980) and in laboratory animals (Table 2) , there do not appear to be any data or in vivo work in dogs. Therapy of viral-infections of the central nervous system is covered by Griffin (1991) .
Porcine viruses
Transmissible gastroenteritis virus (TGEV) was reported to be insensitive in vitro to amantadine (Dimitrov, 1983 ; E.R. Rollinson, unpublished observations) the pyrophosphate analogues PFA and PM (Dimitrov, 1983 ; E.R. Rollinson, unpublished observations) leupeptin (Appleyard and Tisdale, 1985) and the fluoropyrimidine nucleosides, FIAC, FMAU, FIAU (E.R. ROllinson, unpublished observations).
However, Ribavirin showed moderate activity in vitro (IC 50 10-100 f.1M) (Krainova et aI., 1983) .
In pigs with TGEV infection, idoxuridine or 6-azauridine treatment was ineffective (Steffenhagen et aI., 1976) , as was isoprinosine (Glasgow and Galasso, 1972) .
In studies against pseudorabies (Aujeszky's disease, SHV-1)in pigs (D. P. Gustafsen et al., personal communication) the highly soluble monophosphate ester disodium salt of Ara-A, Ara-AMP, was used (10 or 20mg kg-1 i.rn, every 8 or 24 h for 5 days) together with the adenosine deaminase inhibitor co-vidarabine (Co-V) (one injection i.m. prior to first Ara-AMP) dose. Although all piglets developed pyrexia and exhibited some degree of nervous system involvement attributable to the virus, treatment did delay the time of onset of clinical signs, but Co-V did little to enhance the effectiveness of Ara-AMP, as all the piglets in this group died.
Further work on experimentalBl-iv-t infection was reported by Rollinson et al. (1988) . Two experimental porcine models of SHV-1 were compared for assessing the efficacy of a nucleoside analogue, BW B759U (9-[1,3dihydroxy-2-propoxymethyl] quanine, DHPG. While signs were the same following intranasal inoculation and in-contact transmission of SHV~1 , the time-course of the disease was different. There was less variation in clinical signs between pigs following artificial infection, but the disease was more severe, making this a consistent but also more stringent test system. DHPG was administered intramuscularly in divided twice daily doses at 50 mg kg-1 to three-week-old piglets in these two SHV-1 disease models. In artificially infected animals, in which treatment was begun 1.5h preinfection and continued for six days, there was a delay in the onset of clinical signs (4.8 compared with 3.2 days), a 1 log10 reduction in virus shedding, and a 1 to 2 log10 reduction in Virus recovered from tissues, but all the treated piglets died from AD. In contrast, none of the DHPG treated piglets in the in-contact model system died during the eight-day medication period, although two piglets died subsequently. Mean serum concentrations of DHPG 2 h after intramuscular dosing were about 45 f.1M, at 9 h 15-20 f.1M and at 17 h 3.5 f.1M. The in vitro IC 50 of DHPG against SHV-1 varied from 1.5 to 80 f.1M depending on the cell line in which the assay was carried out. There were no overt signs of DHPG toxicity in the treated piglets.
While the porcine rotaviruses were insensitive in vitro to ribavirin, bovine rotavirus proved moderately sensitive (IC 50 10-100 f.1M) and Rotavirus from both cattle and pigs were moderately sensitive to DHPA (D. F. Smee et aI., personal communication; R. W. Sidwell et aI., personal communication). Bovine rotavirus was insensitive to HPA-23 in vitro (Evrard etal., 1984) , but moderately sensitive to HulFNu 2 (Dagenais et aI., 1981; Schwers et al.,1985) .
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African swine fever virus has been the subject of numerous in vitro studies (reviewed by Gil-Fernandez et aI., 1987) , but there do not appear to be any published reports of studies in pigs. A system for the larqe-scale production of purified mature recombinant porcine IFN-u has been described recently (Lefevre et aI., 1990) . The availability of this molecule will open up a new field for in vivo investigations concerning the role of IFN in pigs and its possible prophylactic use.
Bovine viruses
In vivo studies in cattle on therapy of bovine rotaviruses include those with HulFN 2, which showed moderate protection (A. Schwers et al., personal communication; van den Broecke et al., 1984; Schwers et al., 1985) . Bacterially produced HulFN was administered at a rate of 10 6 IU kg-1 , l.m., daily for 3 or 4 days, to three colostrumdeprived calves inoculated orally 2-24 h post birth with approximately 10 8 p.f.u. rotavirus (strain 81/36F). Two treated calves remained clinically normal and one presented with transient diarrhoea only, while in the four untreated controls, diarrhoea persisted for at least 48 h and one calf died. Equivocal results were obtained when Hu-IFN was tested against BHV-1 in cattle. A dose of 10 6 IU kg-1 was, administered l.rn, for 6 days to 3 heifers, commencing 24 h prior to intranasal infection with 5 x 10 7 p.f.u. BHV-1. Treatment did not reduce virus excretion or nasal discharge, and did not prevent the establishment of latency (C. van den Broecke et aI., personal communication).
Babiuk and co-workers have investigated the potential of recombinant bovine interferon alpha (BoIFNu) against the viruses implicated in bovine respiratory disease. Treatment of bovine alveolar macropahges or polymorphonuclear granulocytes with BolFNu resulted in reduced BHV-1 replication and spread Babiuk et al., 1984) . The increase in leukocyte function was not always apparent; in some instances, the random and chemotaxin-induced migration of cells were suppressed. Of the other bovine viruses against which BolFNu has been tested in vitro, vesicular stomatitis virus proved the most susceptible (inhibited by 1 to 10 IU rnl"), followed by bovine virus diarrhoea virus (1 031U rnr') and parainfluenza-3 virus (1621U mr'), with BHV-1 being the least susceptible (>1000 IU mr') (Czarnieckiet al., 1985) .
In in vivo experiments, treatment of calves (groups of 5) with BolFNu (10 or 25 mg per animal) had a definite effect on their ability to withstand a virulent challenge 48 h later with BHV-1, followed 4 days later by Pasteurella haemolytica infection Czarnieki et al., 1985) . A 1-mg dose did not effectively reduce clinical scores relative to the control placebo group. At the higher dose rate, reductions in pyrexia, clinical signs, death, and lung pathology were observed in this disease model. However, as found with Hu-IFN above, virus excretion was not reduced significantly, even in those animals protected against challenge, suggesting that Bol FNa. may have more of an immunomodulatory effect than a direct antiviral effect in this model . It is notable that there was no difference in the level of intranasal interferon secreted by control or interferon-treated animals, implying that interferon treatment did not affect the production of endogenous interferon. Of all the viruses implicated in the initiation of 'shipping fever', BHV-1 is the least sensitive in vitro to BoIFNa.and, since treatment of calves resulted in reduced clinical signs of the disease induced by this virus, it is probable that treatment with BoIFNa.may prove more beneficial with respect to the other viruses involved in this disease complex.
When the IFN inducer Poly I:C was given to calves, 1 mg kg-1 i.v., 3h prior to BHV-1 challenge, it did not prevent infection, although the severity of respiratory disease and pneumonic lesions in the lungs were reduced (Theil et aI., Sidwell et al. (1977) Ara-T ++ Aswell et al. (1977 ) Gentry et al. (1979 5-Me-Ara-C ++ Aswell et al. (1977 ) Gentry et al. (1979 Ara-A +++ Aswell et al. (1977 ) Gentry et al. (1979 Ara-Hxrnp +++ Allen et al. (1975) ACV +++ Rollinson and White (1983) OHPG ++++ Rollinson and White (1983) Polyl:C Nemes et al. (1969) Janis and Habel (1972) OHPA +++ Sodja and Holy (1980) Sodja (1986) l3-phenylserine Pons and Preston (1961) ).Another IFN inducer, ABPP, also showed activity in reducing the duration and extent of clinical signs, virus excretion, and lung lesions in BHV-1 challenged calves; the drug was administered either 12 h prior to BHV-1 exposure or 6h post exposure, and given once daily (1 g per calf) for 6 consecutive days (Hamdy and Stringfellow, 19aO) .
In vitro experiments showed that levamisole consistently enhanced both macrophage and lymphocyte functions with a resultant increase in o-tnterferon production (Babiuk et al., 19a4) . However, in experiments in cattle to determine how far levamisole could be used to obviate the stress-related immunosuppression associated with shipping fever, variable results were obtained. In one case, the levamisole was administered (6mg kg-1 ) in combination with a live-attenuated BHV-1 vaccine. In normal unstressed animals, levamisole administration at the time of vaccination resulted in a decreased antibody and cell-mediated response to BHV-1. However, if animals were transported and then treated with levamisole, there appeared to be an enhanced antibody response and concurrent reduction in virus excretion. In another large field trial, levamisole administration had no effect on morbidity due to respiratory disease, but was associated with improved daily weight gain and feed conversion.
The sugar analogues 2-deoxy-D-glucose (2-dG) and glucosamine have been evaluated against two bovine respiratory viruses. Daily injection of 2-dG (20mg kg-1 Lv.) had no protective or ameliorating effect against experimental respiratory tract infection in calves caused by BHV-1. However, ocular instillation of the drug markedly reduced the severity of conjunctivitis and keratoconjunctivitis, when given either at the time of infection or after clinical signs developed (Mohanty et aI., 19aO) . Thus, topical 2-dG may have chemotherapeutic potential in conjunctivitis in cattle caused by BHV-1. A similar dose regimen, but at 10mg kg-1, was used to investigate the effect of 2-dG against experimental bovine respiratory syncytial virus infection in calves (Mohanty et al., 1981) . Respiratory tract disease due to this virus is usually less severe than that caused by BHV-1. Although i.v, treatment protected against the development of mild clinical signs of respiratory disease, there was no effect on the gross and histopathological changes produced by the virus in the lungs. The drug was ineffective when administered after the onset of clinical disease and there was no added advantage in administering it intranasally at the time of infection. Ribavirin treatment, on the other hand, when given 3 days post RSV challenge (72mg i.v., Day 1 followed by 60 mg on Days 2 and 3), did lead to a reduction in symptoms of disease, and there were no adverse systemic effects of therapy (Bartzatt and Anderson, 1989) .
Further studies on ribavirin treatment of cattle with pneumonia (n = 14), diarrhoea (n = 10) or malignant catarrhal fever (n = 1) were reported by V. Ya. Mozgiz et al. (personal communication) . Calves were treated orally at 5mg kg-1, 3-4 times daily, for 3-5 days. All treated animals recovered and had better weight gains than the controls, five of which died. Gilliam and Field (1992) established that HPMPC is active against the BHV-1 in tissue culture at a concentration of4 fL9 rnl". They then designed an experimenttotest the efficacy of a single dose of HPMPC in experimentally infected calves. Eleven calves, shown to be free from BHV-1 by serological tests, were infected by means of intranasal instillation. All untreated animals developed clinical signs including fever and ocular and nasal discharges. High titres of virus were recovered from nasal and ocular secretions. An injection of 20mg kg-1 of HPMPC given once on the day before, or day after virus inoculation had a profound affect on clinical signs. The therapeutic dose reduced virus shedding in all sites by several log10. The development of antibody to the infecting Virus was different in the treated animals compared to untreated controls. It was of interest that the animals which had been treated during the acute infection showed a reduced and different pattern of virus shedding on reactivation. A therapeutic dose of HPMPC was also able to modify the pattern of virus reactivation in animals which had not been treated during the initial infection. These findings are particularly important since they demonstrate efficacy of a single dose of the antiviral agent HPMPC against an alpha herpesvirus in its natural host.
Malignant catarrhal fever virus (MCFV) is slightly sensitive to acyclovir in vitro but no activity was demonstrable in a rabbit disease model of MCF (N. Edington, personal communication).
Bovine leukaemia virus was moderately sensitive to Ribavirin in vitro (Sidwell and Smee, 1981) , and to suramin, HPA-23 and AZT (Reiner et al., 1989) while cyclophosphamide treatment of BLV-infected cattle was ineffective (Van der Maaten, 1984) . Suramin treatment of BLV-infected sheep (20 mg kg-1 per week from week 10 to week 16 post infection) lead to a significant, but transient, disappearance of P24 antigen and did not affect the titre of anti-P24 or gp51 antibodies (Burkhardt and Ros, 1989; Rosenthal et el., 1990) .
Equine viruses
A small-scale trial by Bryans et al. in 1966 demonstrated that oral treatment with amantadine (by intubation, twice daily for 11 days, at 20mg kg-1 dose-1) SUbstantially reduced equine influenza virus excretion in experimentally infected horses. The authors suggest that (assuming comparable activity existed for future antigenic variant viruses) amantadine might be used to limit the spread of disease caused by such variant influenza virus until such time as an updated vaccine was licensed.
In a study of 439 clinical cases (Thein and Hechler; , a radiation-inactivated preparation of avipoxvirus (pind-Avi), an inducer of 'paraimmunity' in the horse, was useful in preventing equine influenza and respiratory disease in foals, but it was of no value in treating acute or chronic respiratory disease in horses.
Provided that therapy is administered frequently, idoxuridine and acyclovir have been used with success against herpetic keratitis in horses (Matthews and Handscombe, 1983; Bedford, 1985; N. Irby, personal communication) . Although ACV was effective in preventing EHV-1 induced mortality (from hepatitis) in Syrian hamsters (Rollinson and White, 1983) , preliminary investigations on the pharmacokinetics of ACV in the horse (Rollinson, 1988) indicated that it is unlikely to be a suitable antiviral for treatment of equine rhinopneumonitis, because of short half-life and poor absorption from the gut. A therapeutic effect could possibly be achieved in the horse after dosing at 20 mg kg-1 i.v, every8h, but such a dose regimen is unlikely to be acceptable in practice. Moreover, i.v, administration was regularly followed by symptoms of colic, possibly caused by crystalluria. Relatively low plasma levels were obtained following oral dosing as a result of poor absorption. It would appear that the pharmacokinetics of ACV in the horse differ markedly from humans and other species. When ACV was used to treat foals which had been naturally infected in utero by EHV-1, there was no response to therapy (5mg kg-1 i.v. 2-3 times daily) (D. Powell, personal communication). Of possibly much greater potential is the ACV congener DHPG, which has outstanding in vitro activity against EHV-1 IC so 0.06 fL9 mr' and in vivo in the hamster disease model (ED so 0.4 fL9 mr' day-l) (Rollinson and White, 1983) . In a small experimental study, four ponies received DHPG orally, was the level of virus shedding. The duration of virus shedding appeared to be unaffected by treatment, as were the serological responses of the ponies to infection (E. A. Rollinson, unpublished observations) . In a further study to investigate the possible use of DHPG in treating EHV-1 infected pregnant mares, it appeared that DHPG did not cross the placenta in late gestation (P. Rossdale and E. A. Rollinson, unpublished observations) . Importantly, DHPG appeared to be free of the acute adverse effects produced by ACV in the horse. Activity in vitro of DHPG has also been reported for equine coital exanthema (EHV-3, IC so 0.16 JLg mr') (Smith et aI., 1983 ).
Field and colleagues (Field and Awan 1990; H. J. Field et al., personal communication; 1992) have reported on the marked effects of HPMPA ([S]-9-[3-hydroxy-2-phosphonyl methoxypropyl] adenine) on the pathogenesis of EHV-1 in a murine model, and more recently in horses (Gibson et al., 1992) . When treatment in mice was commenced before infection, virus replication in the respiratory tract was virtually eliminated, viraemia was cleared and progression of clinical signs was reversed. Effects of therapy were less marked-when treatment was begun post-infection. PMEA was only marginally effective in this murine model. The in vivo data reflected the in vitro results, where HPMPA had an IC so of 0.1 JLg rnr', with PMEA some 10-fold less active. The mode of action of HPMPA differs from that of DHPG, in that it acts independently of the virus encoded thymidine kinase, and TKmutants remain sensitive to HPMPA.
InnoVet is submitting a US licence application for its immunostimulant IVET-629, in 1992, for treatment of chronic equine respiratory diseases. IVET-629 exhibits selective stimulation of B-Iymphocytes, which may have some effect on resistance to reinfection (Anon, 1992a) .
Potential problem of drug resistance
If antiviral drugs become available for general use, it is probable that resistant viral strains will develop, as bacterial strains have done to antibacterials. The methods for evaluating resistance and the mechanisms of resistance to antiviral agents are dealt With elsewhere (Field, 1983 (Field, , 1988 Larder and Darby, 1984) . Although it is well known that drug resistance may be acquired by viruses in Vitro, little is yet known of the significance of resistance in the clinical situation. For example, mutants of FIVresistant to AZT have been reported (Remington et aI., 1991) . Initial indications regarding one kind of resistance, herpes simplex virus type 1 to ACV, are encouraging, in that some resistant strains of HSV-1 (which manifest resistance by virtue of being thymidine-kinase negative) tend to have reduced virulence (Field, 1983) . Similarly, when comparing the pathogenicity for mice of various vaccine strains of SHV-1, van Oirschot and Gielkens (1984) found that mice Antiviral chemistry in veterinary medicine 321 were resistant only to the strain which did 'not induce thymidine kinase in pig kidney cells, but were susceptible to the TK+ strains. Ben-Poratt et al. (1984) have reported that a TK-strain of SHV-1 was avirulent in swine. Combination therapy may offer a means by which the development of drug resistance can be reduced, by the use of two drugs with different mechanisms of inhibition. Reports on the combined effects of antiviral agents on Viruses of veterinary importance are scant, excepting for those on use of IFN and nucleoside analogues, reported under feline leukaemia and FIV in Part 1.
Concluding remarks
The success of acyclovir (ZOVIRAX®) and zidovudine (RETROVIR®) and the huge research and development commitment throughout the human pharmaceutical companies towards antiretroviral compounds is undoubtedly improving the prospects for the availability of specific antiviral compounds for veterinary use, especially for FeLV and FIV. Non-specific immune modulators, with antiviral activity are now nearing the market, e.g. InnoVet's IVET-629 for the treatment of equine respiratory disease and shipping fever in cattle. However, there still remains the economic conundrum, of how far the high costs of development and registration of specific veterinary antivirals per se will be justified by subsequent financial return from sales. The advent of antivirals with a relatively broad spectrum of activity but low toxicity, such as HPMPA and HPMPC, is encouraging in this respect. There is likely to be continued use, in animals, of antivirals which are registered for human use only. Additionally, antiviral agents are extremely useful as research tools per se, as opposed to chemotherapeutic agents alone, and can be used selectively to define and/or generate virus isolates with particular profiles, for example. There are still many obstacles to overcome in the practical use of veterinary antivirals, especially that of prompt diagnosis to facilitate early treatment. Further progress in the development of diagnostic tools will be a prerequisite to successful veterinary antiviral chemotherapy. Alternatively, it may be possible to anticipate when viral infections may threaten and to treat them strategically. Prophylactic treatment may well be worthwhile, e.g. when animals are subjected to stress situations, such as being transported, marketed, mixed with other stock, racing or competing, etc., or are likely to be exposed to infection for some other reason, although suitable withdrawal periods would have to be defined for competition horses, for example. Breeding stock, particularly of horses, cattle, pig, and sheep, where viruses are important causes of abortion and infertility, are obvious targets for antiviral chemotherapy. The increase in artificial insemination and embryo transfer, especially in cattle, offers another possibility for the use of antivirals in preventing the transmission of venereally associated viral agents.
Antiviral chemotherapy and vaccination need not be mutually exclusive, both approaches being used in certain circumstances for the control of virus diseases, e.g. vaccine breakdown, or where an animal is likely to suffer adverse reactions to vaccination. Chemotherapy and vaccination were proposed as a possible control strategy for highly viruent influenza viruses in chickens, especially under conditions where eradication is not a viable option (Webster et al., 1985 (Webster et al., , 1986 . Either measure alone did not prevent development of the disease and mortality, but simultaneous administration of an H5N2 vaccine and amantadine protected birds from infection.
There is still much to be learned concerning the pathogenesis of virus infections of domestic animals, birds, and fish. Only by improving our understanding ofthe many factors involved in the disease process and undertaking concomitant studies on pharmacokinetics/pharmacodynamics will it become possible to design effective chemotherapeutic regimens. Technology is advancing regarding the targeting of drugs to the site of infection by using prod rugs (Krenitsky et al., 1984) , by using protein carriers (Fiume et al., 1988) , by modifying drugs to resist metabolic degradation, by use of liposomes or polymers to encapsulate/allow slow or pulse release (Canonico et al., 1984; Kende et al., 1985; Koff and Fidler, 1985) . These advances in drug delivery will be of particular importance in veterinary practice, since repeated dosing is not always practicable or cost effective. In this context, the reported efficacy of a single dose of the antiviral agent HPMPC against BHV-1 infection in cattle is particularly exciting, and suggests that it will be possible to overcome the hurdle of practicable administration. Overall, specific veterinary antiviral chemotherapy is having a continuing, significant and rewarding role, now and in the future, particularly for the retrovirus diseases of cats, and herpesvirus infections of many domestic animals.
